SPOTLIGHT: Sepracor touts data

Sepracor says its experimental therapy for seasonal allergic rhinitis hit its primary and secondary endpoints in a mid-stage trial. Omnaris "demonstrated a statistically significant reduction in 24-hour total nasal symptom scores versus placebo." Release | Report

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.